Elevance Health Q2 revenue rises 0.8% to $49.8B; EPS falls to $6.71, guidance raised
Elevance Health reported second-quarter 2026 operating revenue of $49.8 billion, up 0.8% from a year earlier, while diluted earnings per share fell 13.1% to $6.71 from $7.72. The company raised its full-year 2026 diluted EPS guidance to at least $20.10 and its adjusted EPS guidance to at least $27.00, and said it is accelerating targeted investments. For shareholders, the higher outlook comes alongside lower quarterly profit and a higher benefit expense ratio.
Key points
- Operating revenue was $49.8 billion in the second quarter of 2026, up from $49.4 billion a year earlier.
- Diluted EPS was $6.71 versus $7.72 a year earlier; adjusted diluted EPS was $7.45 versus $8.84.
- Full-year 2026 diluted EPS guidance was raised to at least $20.10 and adjusted diluted EPS guidance to at least $27.00.
- Full-year 2026 operating cash flow guidance was raised to at least $6.0 billion; a $1.72 quarterly dividend is payable September 25, 2026.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 15, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.